Regdanvimab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was authorized for medical use in the European Union in November 2021.

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was authorized for medical use in the European Union in November 2021.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1338742550 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

15 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.